Médecins en Hématologie Oncologie en Chine — Page 2

Meng Lingru is a specialist at Hainan Chengmei Hospital and works as Deputy Chief Physician in clinical oncology. With over 20 years of experience, she focuses on diagnosis and treatment of malignant tumors within internal medicine. Her training includes further study in the Department of Medical Oncology at the Cancer Hospital of the Chinese Academy of Medical Sciences.

Lei Jun is a specialist at Hainan Chengmei Hospital, serving as Deputy Chief Physician at the Geriatric Multidisciplinary Diagnosis and Treatment Center. She focuses on Medical Oncology, combining chemotherapy and molecular targeted therapy with precision treatment guided by genetic testing. For international patients, her approach is built around whole-process management for cancers such as lung, breast, stomach, and colorectal cancer.

Dr. Yang Jun is a specialist at Fosun Health and the Director of the Precision Oncology Centre at Foshan Chancheng Hospital. Fosun Health highlights his CyberKnife expertise with 6,000+ treatment cases and positions him as a non-invasive treatment option for cancers across the brain, lung, liver, prostate, and spine. In 2026, Fosun Health also promoted his free one-on-one consultation in Jakarta on June 18.

Dr. Ye Gang is a specialist at Fosun Health Hospitals and Chief Expert in the Department of Medical Oncology. Fosun Health Hospitals lists him as a US Board-Certified Physician in Internal Medicine, Hematology, and Medical Oncology, with experience as a former Director of Medical Oncology and MDT leader at Boao Evergrande International Hospital. His work covers cancers and hematologic malignancies, including breast cancer and lung cancer, with complex diagnostic and treatment pathways such as CAR-T cell therapy mentioned in his specialist profile.

Fan Shunwu is a professor at Sir Run Run Shaw Hospital with more than 40 years of medical experience. His work is linked to bone metastasis-related diagnosis and treatment, addressing challenges such as late detection on X-ray and CT. SRRSH article content describes a proposed early-stage tumor-cell killing strategy by targeting tumasteoclasts.